Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective

Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of intensive care medicine Jg. 35; H. 5; S. 415
Hauptverfasser: Griffin, Benjamin R, Gist, Katja M, Faubel, Sarah
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.05.2020
Schlagworte:
ISSN:1525-1489, 1525-1489
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the prevention and treatment of the disease. A lack of efficacy in drug trials led to the concern that AKI was not being diagnosed early enough for an effective intervention and that a rise in serum creatinine itself is not a sensitive-enough marker. Researchers have been searching for novel biomarkers that can not only assess a decline in kidney function but also demonstrate structural damage to the kidney and at time points earlier than increases in serum creatinine measurements allow. Over the past 10 years, there have been 3300 new publications and hundreds of new biomarkers investigated, yet concern still remains regarding AKI biomarker performance. The AKI biomarkers are yet to be widely utilized in clinical practice, leading some to question whether AKI biomarkers will ever reach their initial promise. However, we believe that biomarkers are an important part of current and future AKI research and clinical management. In this review, we compare the historical contexts of acute myocardial ischemia and AKI biomarker development to illustrate the progress that has been made within AKI biomarker research in a relatively short period of time and also to point out key differences between the disease processes that have been barriers to widespread AKI biomarker adoption. Finally, we discuss potential paths by which biomarkers can lead to appropriate AKI treatment responses that lower morbidity and mortality.
AbstractList Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the prevention and treatment of the disease. A lack of efficacy in drug trials led to the concern that AKI was not being diagnosed early enough for an effective intervention and that a rise in serum creatinine itself is not a sensitive-enough marker. Researchers have been searching for novel biomarkers that can not only assess a decline in kidney function but also demonstrate structural damage to the kidney and at time points earlier than increases in serum creatinine measurements allow. Over the past 10 years, there have been 3300 new publications and hundreds of new biomarkers investigated, yet concern still remains regarding AKI biomarker performance. The AKI biomarkers are yet to be widely utilized in clinical practice, leading some to question whether AKI biomarkers will ever reach their initial promise. However, we believe that biomarkers are an important part of current and future AKI research and clinical management. In this review, we compare the historical contexts of acute myocardial ischemia and AKI biomarker development to illustrate the progress that has been made within AKI biomarker research in a relatively short period of time and also to point out key differences between the disease processes that have been barriers to widespread AKI biomarker adoption. Finally, we discuss potential paths by which biomarkers can lead to appropriate AKI treatment responses that lower morbidity and mortality.Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the prevention and treatment of the disease. A lack of efficacy in drug trials led to the concern that AKI was not being diagnosed early enough for an effective intervention and that a rise in serum creatinine itself is not a sensitive-enough marker. Researchers have been searching for novel biomarkers that can not only assess a decline in kidney function but also demonstrate structural damage to the kidney and at time points earlier than increases in serum creatinine measurements allow. Over the past 10 years, there have been 3300 new publications and hundreds of new biomarkers investigated, yet concern still remains regarding AKI biomarker performance. The AKI biomarkers are yet to be widely utilized in clinical practice, leading some to question whether AKI biomarkers will ever reach their initial promise. However, we believe that biomarkers are an important part of current and future AKI research and clinical management. In this review, we compare the historical contexts of acute myocardial ischemia and AKI biomarker development to illustrate the progress that has been made within AKI biomarker research in a relatively short period of time and also to point out key differences between the disease processes that have been barriers to widespread AKI biomarker adoption. Finally, we discuss potential paths by which biomarkers can lead to appropriate AKI treatment responses that lower morbidity and mortality.
Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of the high incidence and poor outcomes associated with AKI, there has been significant interest in the development of new therapies for the prevention and treatment of the disease. A lack of efficacy in drug trials led to the concern that AKI was not being diagnosed early enough for an effective intervention and that a rise in serum creatinine itself is not a sensitive-enough marker. Researchers have been searching for novel biomarkers that can not only assess a decline in kidney function but also demonstrate structural damage to the kidney and at time points earlier than increases in serum creatinine measurements allow. Over the past 10 years, there have been 3300 new publications and hundreds of new biomarkers investigated, yet concern still remains regarding AKI biomarker performance. The AKI biomarkers are yet to be widely utilized in clinical practice, leading some to question whether AKI biomarkers will ever reach their initial promise. However, we believe that biomarkers are an important part of current and future AKI research and clinical management. In this review, we compare the historical contexts of acute myocardial ischemia and AKI biomarker development to illustrate the progress that has been made within AKI biomarker research in a relatively short period of time and also to point out key differences between the disease processes that have been barriers to widespread AKI biomarker adoption. Finally, we discuss potential paths by which biomarkers can lead to appropriate AKI treatment responses that lower morbidity and mortality.
Author Faubel, Sarah
Gist, Katja M
Griffin, Benjamin R
Author_xml – sequence: 1
  givenname: Benjamin R
  surname: Griffin
  fullname: Griffin, Benjamin R
  organization: Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
– sequence: 2
  givenname: Katja M
  surname: Gist
  fullname: Gist, Katja M
  organization: Department of Pediatrics, The Heart Institute, University of Colorado, Aurora, CO, USA
– sequence: 3
  givenname: Sarah
  surname: Faubel
  fullname: Faubel, Sarah
  organization: Renal Section, Veterans Affairs Eastern Colorado Health Care System, Denver, CO, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30654681$$D View this record in MEDLINE/PubMed
BookMark eNpNkD1PwzAYhC1URD9gZ0IeWQK2Ezs2WykfragACZgjx3kDLmlcbKdS_z0RFInpbnjupLsxGrSuBYROKbmgNM8viZScCCGolCzjKT1AI8oZT2gm1eCfH6JxCCtCaMpSeoSGKRE8E5KOEMw676GN-CXq2AXsavzottDga-vW2n-CD7h2HscPwDdWv7cu2B9qaroI-MFWLezwol11fneFp3huQ3TeGt3g5z67ARPtFo7RYa2bACd7naC3u9vX2TxZPt0vZtNlYjghMZF1WitOs7xKVSVqpjSttSJcACml4WXNKsoMY1LnlNDcVEIBE5ArXoKoSmATdP7bu_Huq4MQi7UNBppGt-C6UDCaq1T2Z5EePdujXbmGqth42-_dFX_XsG8kame1
CitedBy_id crossref_primary_10_3389_fphar_2021_798642
crossref_primary_10_1007_s10157_022_02300_2
crossref_primary_10_34067_KID_0003552020
crossref_primary_10_1038_s41581_020_0276_7
crossref_primary_10_1186_s12967_022_03687_y
crossref_primary_10_1016_j_cllc_2022_01_003
crossref_primary_10_1053_j_jvca_2024_07_016
crossref_primary_10_1128_AAC_01650_19
crossref_primary_10_1136_bmjopen_2020_046274
crossref_primary_10_3390_cells13191613
crossref_primary_10_1007_s40140_019_00325_0
crossref_primary_10_3390_nu11092087
crossref_primary_10_1371_journal_pone_0316205
crossref_primary_10_1080_0886022X_2023_2205958
crossref_primary_10_3389_fphys_2020_00139
crossref_primary_10_3390_jcm13226720
crossref_primary_10_1371_journal_pone_0311755
crossref_primary_10_5005_jp_journals_10071_23398
crossref_primary_10_1002_prp2_695
crossref_primary_10_1038_s41390_022_02269_4
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1177/0885066618824531
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1525-1489
ExternalDocumentID 30654681
Genre Historical Article
Journal Article
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: T32 DK007135
GroupedDBID ---
-TM
.2E
.2F
.2G
.2J
.2N
.XZ
01A
0R~
1OC
1~K
29K
31R
31S
31U
31X
31Y
31Z
31~
4.4
53G
54M
5GY
5RE
5VS
8-1
AABMB
AABOD
AACKU
AACMV
AACTG
AADUE
AAEJI
AAEWN
AAGGD
AAGLT
AAGMC
AAJIQ
AAJOX
AAJPV
AAKGS
AANSI
AAPEO
AAPII
AAQDB
AAQQT
AAQXH
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAXOT
AAYTG
AAZBJ
ABAFQ
ABAWP
ABCCA
ABCJG
ABDWY
ABEIX
ABFWQ
ABHKI
ABHQH
ABIDT
ABJNI
ABJZC
ABKRH
ABLUO
ABPGX
ABPNF
ABQKF
ABQXT
ABRHV
ABUJY
ABVFX
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACFYK
ACGBL
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACLHI
ACLZU
ACOFE
ACOXC
ACROE
ACRPL
ACSIQ
ACUAV
ACUIR
ACXKE
ACXMB
ACXQS
ADBBV
ADDLC
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADNON
ADRRZ
ADSTG
ADTBJ
ADUCT
ADUKL
ADVBO
ADYCS
ADZZY
AECGH
AECVZ
AEDTQ
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFKBI
AFMOU
AFQAA
AFUIA
AFWMB
AFZJQ
AGHKR
AGKLV
AGNHF
AGPXR
AGQPQ
AGWFA
AGWNL
AHDMH
AHHFK
AIGRN
AIIQI
AJABX
AJAOE
AJEFB
AJGYC
AJMMQ
AJSCY
AJVBE
AJXAJ
ALKWR
ALMA_UNASSIGNED_HOLDINGS
AMCVQ
ANDLU
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B3H
B8M
B8O
B8R
B8Z
B93
B94
BBRGL
BDDNI
BKIIM
BKSCU
BPACV
BSEHC
BWJAD
BYIEH
C45
CAG
CBRKF
CDWPY
CFDXU
CGR
COF
CORYS
CQQTX
CS3
CUTAK
CUY
CVF
D-I
DB0
DC-
DC.
DC0
DD-
DD0
DE-
DF0
DO-
DOPDO
DV7
DV9
D~Y
EBS
ECM
EIF
EJD
EMOBN
F5P
FEDTE
FHBDP
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HVGLF
HZ~
IAO
IEA
IHE
IHR
INH
INR
IVC
J8X
K.F
K.J
N4W
N9A
NPM
O9-
OVD
P.B
P2P
Q1R
Q7K
Q7L
Q7R
Q7U
Q7X
Q82
Q83
ROL
S01
SASJQ
SAUOL
SBI
SCNPE
SDB
SFB
SFC
SFK
SFT
SGA
SGO
SGP
SGR
SGV
SGX
SGZ
SHG
SNB
SPJ
SPP
SPQ
SPV
SQCSI
STM
TEORI
WH7
YFH
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
7X8
AJHME
ID FETCH-LOGICAL-c500t-8f3f95147d39d6f29a1fa9056e0b8c5bf2d12c228a71017cd69e26e795be6dbe2
IEDL.DBID 7X8
ISICitedReferencesCount 27
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000523042100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1525-1489
IngestDate Sun Sep 28 06:55:08 EDT 2025
Mon Jul 21 05:32:46 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords NGAL
acute kidney injury
biomarkers
TIMP2 IGFBP7
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c500t-8f3f95147d39d6f29a1fa9056e0b8c5bf2d12c228a71017cd69e26e795be6dbe2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/7333543
PMID 30654681
PQID 2179388820
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2179388820
pubmed_primary_30654681
PublicationCentury 2000
PublicationDate 2020-05-01
PublicationDateYYYYMMDD 2020-05-01
PublicationDate_xml – month: 05
  year: 2020
  text: 2020-05-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of intensive care medicine
PublicationTitleAlternate J Intensive Care Med
PublicationYear 2020
SSID ssj0013231
Score 2.3903773
SecondaryResourceType review_article
Snippet Acute kidney injury (AKI) is a common and serious medical condition associated with significant increases in morbidity, mortality, and cost of care. Because of...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 415
SubjectTerms Acute Kidney Injury - diagnosis
Acute Kidney Injury - history
Biomarkers - analysis
History, 20th Century
Humans
Kidney Function Tests - history
Title Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective
URI https://www.ncbi.nlm.nih.gov/pubmed/30654681
https://www.proquest.com/docview/2179388820
Volume 35
WOSCitedRecordID wos000523042100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAabNNHGi-yPhZFt-xBYW-lzQMq2q7b3QX_vZM2Sz14ELz01IaSfDP5JjP5BqELLlkYSkcR2Ewk8WWaEfB5gviRcKXWQDJ0rTP7zOI4Go340B64VbascuETa0ctS2HOyC-pQRKEa9S5Hn8S0zXKZFdtC41l1PGAyhhUs9HPLILX6KXSgADt522a8hKMKzDU3YUR_cC2mPuVYNYbTX_zv7-4hTYsxcS9BhPbaEkVO2htYJPou0hZTSZsiOaswqXGcTlX7_gmLz9Mtc6kwkBlMVBDfNdU4uX1Wz0xmyr8lMtCfeHH4g2W4wr3cKs0goft1c099Nq_f7l9ILbbAhGB40xJpD0NdMtn0uMy1JSnrk458CPlZJEIMk2lSwWlUcqMGQsZckVDxXiQqVBmiu6jlaIs1CHCEIVx12NOGkTKl4CRzChV-TCYp13KdBedLyYwATSbFEVaqHJWJe0UdtFBswrJuJHdSOoe92HkHv3h62O0Tk1gXFcmnqCOBltWp2hVzKd5NTmrYQLPeDj4BuRSxoY
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+Status+of+Novel+Biomarkers+for+the+Diagnosis+of+Acute+Kidney+Injury%3A+A+Historical+Perspective&rft.jtitle=Journal+of+intensive+care+medicine&rft.au=Griffin%2C+Benjamin+R&rft.au=Gist%2C+Katja+M&rft.au=Faubel%2C+Sarah&rft.date=2020-05-01&rft.issn=1525-1489&rft.eissn=1525-1489&rft.volume=35&rft.issue=5&rft.spage=415&rft_id=info:doi/10.1177%2F0885066618824531&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-1489&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-1489&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-1489&client=summon